Myovant Sciences Ltd MYOV:NYSE

RT Quote | NYSE | USD
Last | 05/12/21 EDT
20.67quote price arrow up+0.91 (+4.61%)
Volume
955,589
52 week range
11.55 - 30.90

...

Loading . . .
  • Open19.53
  • Day High21.50
  • Day Low19.52
  • Prev Close20.67
  • 52 Week High30.90
  • 52 Week High Date12/28/20
  • 52 Week Low11.55
  • 52 Week Low Date05/14/20

Key Stats

  • Market Cap1.877B
  • Shares Out90.80M
  • 10 Day Average Volume0.67M
  • Dividend-
  • Dividend Yield-
  • Beta2.88
  • YTD % Change-25.16

KEY STATS

  • Open19.53
  • Day High21.50
  • Day Low19.52
  • Prev Close20.67
  • 52 Week High30.90
  • 52 Week High Date12/28/20
  • 52 Week Low11.55
  • 52 Week Low Date05/14/20
  • Market Cap1.877B
  • Shares Out90.80M
  • 10 Day Average Volume0.67M
  • Dividend-
  • Dividend Yield-
  • Beta2.88
  • YTD % Change-25.16

RATIOS/PROFITABILITY

  • EPS (TTM)-2.66
  • P/E (TTM)-7.76
  • Fwd P/E (NTM)-8.18
  • EBITDA (MRQ)-245.662M
  • ROE (MRQ)-622.01%
  • Revenue (MRQ)34.71M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-687.61%
  • Debt To Equity (MRQ)-115.90%

EVENTS

  • Earnings Date08/09/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Myovant Sciences Ltd

There is no recent news for this security.

Profile

MORE
Myovant Sciences Ltd, is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment women’s health and endocrine diseases. Its lead product candidate is Relugolix, which is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the...
Myrtle Potter
Chairman
David Marek
Chief Executive Officer
Frank Karbe
Chief Financial Officer
Matthew Lang
General Counsel
Address
Ste 1 3rd Fl, 11/12 St. James's Square
London
SW1Y 4LB
United Kingdom

Top Peers

SYMBOLLASTCHG%CHG
CYTK
Cytokinetics Inc
24.32+0.55+2.31%
MORF
Morphic Holding Inc
49.25+1.31+2.73%
SRNE
Sorrento Therapeutics Inc
6.58-0.40-5.73%
DCPH
Deciphera Pharmaceuticals Inc
33.01-0.52-1.55%
HRTX
Heron Therapeutics Inc
17.41-1.07-5.79%